Search Results

The Bayer ADVIA Centaur assay is an automated immunoassay analyzer designed to perform in vitro diagnostic immunochemical assay analysis on clinical specimens. The system menu will include endocrine, anemia, allergy, reproductive, cardiovascular, oncology, adrenal, bone metabolism, therapeutic drug, and infectious disease assays. All assays are based on chemiluminescent technology.

The ADVIA Centaur system is a stand-alone, continuous operation, immunochemistry analyzer. The system performs the following functions:

• Aspirates and dispenses samples .
• Performs dilutions ●
• Adds reagents .
• Incubates reaction vessels .
• Separates solid and liquid wastes ●
• Measures photon emissions .
• Performs data reduction ●
• Collects and maintains patient demographics and results .

The provided text describes a 510(k) summary for the ADVIA® Centaur automated immunoassay analyzer. This document focuses on demonstrating substantial equivalence to a predicate device rather than presenting a performance study with detailed acceptance criteria and results as would be found for a new diagnostic device or algorithm.

Therefore, much of the requested information regarding acceptance criteria, specific performance metrics, sample sizes, ground truth establishment, and expert involvement is not available within this 510(k) summary. The document highlights the technological characteristics of the device and compares them to its predicate.

Here's an analysis of the provided text based on your request:

1. A table of acceptance criteria and the reported device performance

This document does not provide a table of acceptance criteria and reported device performance in the way typically expected for a clinical performance study. The 510(k) summary focuses on demonstrating substantial equivalence based on technological characteristics and intended use to a predicate device (ADVIA Centaur V2.5). The performance implied is that the new version (V3.0) performs equivalently to the predicate.

The table in the document compares "Features" of ADVIA Centaur V2.5 (K032525) and ADVIA Centaur V3.0. For almost all features, the entry for V3.0 is "same", implying that the performance related to these features is considered equivalent to the predicate. The only differences mentioned are software enhancements and hardware improvements.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is not available in the provided 510(k) summary. 510(k) submissions for automated analyzers like this typically focus on technical specifications and functional equivalence rather than clinical performance studies with specific patient sample test sets unless there's a novel assay or a significant change to existing assays. The comparison is feature-based against the predicate device.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not applicable/available. The document does not describe a clinical study requiring ground truth establishment by experts for a test set. This is a submission for an automated immunoassay analyzer, not an imaging device or diagnostic algorithm that relies on expert interpretation of results for ground truth.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not applicable/available. There is no described test set or clinical study requiring adjudication.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This information is not applicable. The device is an automated immunoassay analyzer, not an AI-assisted diagnostic tool that involves human readers or interpretation of cases.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

The ADVIA® Centaur system is inherently a standalone automated analyzer. Its performance is measured by its ability to accurately and precisely execute immunoassay analysis. The document implicitly supports this by stating it "performs the following functions" (aspirates, dispenses, adds reagents, incubates, separates, measures photon emissions, performs data reduction, collects and maintains data). The comparison to the predicate focuses on its ability to perform these functions similarly ("same").

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

This information is not applicable/available for the device itself in this context. For immunoassay analyzers, "ground truth" typically refers to the known concentrations of analytes in reference materials (calibrators, controls) or validated reference methods for patient samples, which are used to establish accuracy, precision, and linearity of the assays run on the system. The 510(k) summary does not detail the validation studies for specific assays run on the Centaur. It only states the system uses a "Master Curve and a two-point, user-initiated calibration."

8. The sample size for the training set

This information is not applicable/available. This 510(k) submission is for an updated version of an automated immunoassay analyzer, not an AI/ML device that requires a "training set" in the computational sense.

9. How the ground truth for the training set was established

This information is not applicable/available for the same reason as point 8.

Ask a specific question about this device